Establishment of a simpler method for measuring HDL-microRNAs.


Journal

Annals of clinical biochemistry
ISSN: 1758-1001
Titre abrégé: Ann Clin Biochem
Pays: England
ID NLM: 0324055

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 29 4 2018
medline: 4 12 2019
entrez: 29 4 2018
Statut: ppublish

Résumé

MicroRNAs are present not only in exosomes but also in high-density lipoprotein (HDL) and have the potential as biomarkers for various diseases. Various purification methods have been developed to quantify HDL-miRNAs; however, they are unsuitable for clinical applications. Therefore, we aimed to establish a simpler analytical method to quantify HDL-miRNAs for clinical applications. We purified HDL fraction from pooled plasma using a three-step protocol consisting of ultracentrifugation, phosphotungstic acid/MgCl Exosomes and LDL were not detected in the purified HDL fraction. Furthermore, we confirmed that only HDL was purified and that the HDL recovery rate of our method was at least approximately 50%. The threshold cycle values of miR-223, miR-92, miR-146a and miR-150 in the same subject were 32.11 ± 0.58, 32.50 ± 0.35, 34.30 ± 0.70 and 34.91 ± 0.77, respectively ( n = 10). The coefficient of variation values for these miRNAs were 1.08-2.21%. In addition, the standard curve for the quantitative analysis of miRNAs showed high linearity (30-30,000 copies/ μL) with a correlation coefficient of >0.99. The concentrations of HDL-miR-223 and HDL-miR-92 in the plasma of 10 subjects were 1.98 ± 0.32 and 0.90 ± 0.14 copies/mL (×10 We established a simple method for quantifying HDL-miRNAs and improved the sample processing capacity compared with conventional methods.

Sections du résumé

BACKGROUND
MicroRNAs are present not only in exosomes but also in high-density lipoprotein (HDL) and have the potential as biomarkers for various diseases. Various purification methods have been developed to quantify HDL-miRNAs; however, they are unsuitable for clinical applications. Therefore, we aimed to establish a simpler analytical method to quantify HDL-miRNAs for clinical applications.
METHODS
We purified HDL fraction from pooled plasma using a three-step protocol consisting of ultracentrifugation, phosphotungstic acid/MgCl
RESULTS
Exosomes and LDL were not detected in the purified HDL fraction. Furthermore, we confirmed that only HDL was purified and that the HDL recovery rate of our method was at least approximately 50%. The threshold cycle values of miR-223, miR-92, miR-146a and miR-150 in the same subject were 32.11 ± 0.58, 32.50 ± 0.35, 34.30 ± 0.70 and 34.91 ± 0.77, respectively ( n = 10). The coefficient of variation values for these miRNAs were 1.08-2.21%. In addition, the standard curve for the quantitative analysis of miRNAs showed high linearity (30-30,000 copies/ μL) with a correlation coefficient of >0.99. The concentrations of HDL-miR-223 and HDL-miR-92 in the plasma of 10 subjects were 1.98 ± 0.32 and 0.90 ± 0.14 copies/mL (×10
CONCLUSIONS
We established a simple method for quantifying HDL-miRNAs and improved the sample processing capacity compared with conventional methods.

Identifiants

pubmed: 29703104
doi: 10.1177/0004563218775770
doi:

Substances chimiques

Biomarkers 0
Lipoproteins, HDL 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-55

Auteurs

Hiroaki Ishikawa (H)

1 Department of Biochemistry, Fujita Health University School of Health Sciences, Toyoake, Japan.

Hiroya Yamada (H)

2 Department of Hygiene, Fujita Health University School of Medicine, Toyoake, Japan.

Kanako Kondo (K)

3 Department of Clinical Biochemistry, Fujita Health University School of Health Sciences, Toyoake, Japan.

Takeru Ota (T)

3 Department of Clinical Biochemistry, Fujita Health University School of Health Sciences, Toyoake, Japan.

Mirai Yamazaki (M)

3 Department of Clinical Biochemistry, Fujita Health University School of Health Sciences, Toyoake, Japan.

Yoshitaka Ando (Y)

3 Department of Clinical Biochemistry, Fujita Health University School of Health Sciences, Toyoake, Japan.

Genki Mizuno (G)

4 Department of Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Japan.

Eiji Munetsuna (E)

5 Department of Biochemistry, Fujita Health University School of Medicine, Toyoake, Japan.

Koji Suzuki (K)

6 Department of Public Health, Fujita Health University School of Health Sciences, Toyoake, Japan.

Ryoji Teradaira (R)

3 Department of Clinical Biochemistry, Fujita Health University School of Health Sciences, Toyoake, Japan.

Koji Ohashi (K)

3 Department of Clinical Biochemistry, Fujita Health University School of Health Sciences, Toyoake, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH